Market Overview
HIV
Drugs Market is projected to achieve a value of USD 23,370 Million in 2023,
with a linear behavior in the market growth it is forecasted to achieve a value
of USD 32,140 Million by 2033 with a CAGR of 3.90% during the forecast period
2023-2033.
Human
Immunodeficiency Virus Drugs are related with the treatment of HIV. Human
Immunodeficiency Virus (HIV) is a virus that responsible for the condition
known as Acquired Immunodeficiency Syndrome (AIDS). Human Immunodeficiency
Virus (HIV) is the infection of virus which attacks the body’s immune system
which helps to fight against the infection, specifically the CD4 cells also
called as T cells, which help to fight against infections in the body.
Human
Immunodeficiency Virus Drugs which assist to stop the multiplication of Human
Immunodeficiency Virus, helps to decrease further complications. HIV Drugs
markets growth attributed by various factors such as rising HIV patients
particularly among youth, unprotected sexual contacts, uses of contaminated or
nonsterile syringes to healthy people, lack of understanding about the risk
factor.
For
instance, HIV is a major and progressive global public health issue, having
recorded 40.4 million lives globally, with an estimated 38.4 million people
living with the condition at the end of 2021, according to the WHO (World
Health Organization).
Moreover,
there is no any permeant treatment option to cure HIV. Therapeutic treatment which available for this
disease enable to increase the lifespan of patient, increase the quality of
life and control the progression of disease. In recent years Advancements in
Antiretroviral Therapy (ART) have transform the treatment of HIV. The
development of combination therapies and Highly Active Antiretroviral Therapy
(HAART)have significantly improved patient conditions.
COVID 19 pandemic significantly Impacts on the growth of HIV Drugs market due to worldwide lockdown cause disturbance in Import and export drug supply, focusing towards the COVID 19 testing rather than other diseases. Because of that reduce new patient enrollment due to lack of diagnostic test. Thus, COVID-19 makes a negative impact on the growth of market.
Market Scope
Report Attributes |
Description |
Market Size in 2022 |
USD
22,500 Million |
Market Forecast in 2033 |
USD 32,140
Million |
CAGR % 2023-2033 |
3.90% |
Base Year |
2022 |
Historic Data |
2016-2022 |
Forecast Period |
2023-2033 |
Report USP |
Production,
Consumption, company share, company heatmap, company production capacity,
growth factors and more |
Segments Covered |
Drug Type, End-user |
Growth Drivers |
The widespread
adoption of HAART, a combination of different classes of antiretroviral
drugs, has transformed HIV treatment Development of Preventive Medications Antiretroviral Drug Delivery Innovation |
Regional Scope |
North America, Europe, APAC, South
America and Middle East and Africa |
Country Scope |
U.S.; Canada;
U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia;
China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico;
Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies |
Boehringer Ingelheim International GmbH,
Cipla Inc., Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company,
Teva Pharmaceutical Industries Ltd, Gilead Sciences, Inc., Hoffmann-La Roche
Ltd, Pfizer Inc., Aurobindo Pharma, Celltrion Healthcare Co.,Ltd, ViiV
Healthcare. |
Market Dynamics
The
HIV Drugs Market is driven by increasing prevalence of HIV patients, factor
responsible for increasing prevalence includes lack of awareness of mode of
transmission of virus, rise in treatment and diagnosis rate. Moreover, there is
a huge escalation of government initiatives to increase awareness about HIV causes,
available treatment options, symptoms of diseases.
HIV
patients are treated as curing the illness and increasing the quality of life.
As such permanent solution is not available yet to cure the HIV and save
patient life. A wider use of pre-exposure prophylaxis(PrEP) which is a
preventive approach to people who having a high risk of HIV. Pre-exposure
prophylaxis(PrEP) is a drug which acts as a catalyst helps the body to produce
antibodies, which help to fight against diseases causing germs and viruses.
Increasing
the importance of R&D activities and government funding foe research in the
field of Human Immunodeficiency Virus Drugs anticipates the growth of the
market. Moreover, technological advancement enhances the delivery and long
lasting effect of the drugs in HIV. For instance, according to the article
March 2020, published by the National Institutes of Health (NIH), long-acting
injectable nanoformulations of cabotegravir and rilpivirine used for HIV
therapy were in phase III clinical trials. Cabotegravir was in advanced
clinical development for HIV pre-exposure prophylaxis, and these formulations
are expected to give results equivalent to traditional medicines, thus boosting
the growth of HIV drugs market.
Furthermore,
the increasing cost of advance therapeutic treatment and devices hamper the
growth of the market. For overcome this problems government initiatives helps
HIV patients in treatement. For Instance, Indian government run National AIDS
control Organization which is a central funded organization to helps HIV
patients.
Overall,
with the help of existing and combination treatment therapy the HIV Drugs
Market is expected to witness significant growth in the coming years, driven by
the introduction of new therapies and an increasing demand for effective
treatments. Additionally, there is a need for advance and effective research
and development to address the unmet needs of cancer treatment and to develop
safe and effective therapies with lower side effects.
Market Drug Type Analysis
By
Drug Type, the HIV Drugs Market is Categories into Protease Inhibitors, Fusion
Inhibitors, CCR5 Antagonist, Nucleoside, Integrase Inhibitors, Non-Nucleoside
Reverse Transcriptase Inhibitors. The T Nucleoside segment accounts for the
largest share of around 42% of the Market in 2022.
The
Nucleoside Therapy segment dominates the market because the therapeutic
improving outcomes of this segment is greater than the other segments in the
treatment of HIV and co-infection.
Market End-User Analysis
By
End-user, the HIV Drugs Market is Categories into Hospitals & Clinics,
Specialty Centers. The Hospital & Clinics segment accounts for the largest
share of around 54% of the Market in 2022.
Rising
investment in healthcare and increasing hospital facility in developed and
developing market are major factor to drive the segment. Moreover, Hospitals
are the primary healthcare facility where patient come for treatment. Also
hospital having the infrastructure to diagnosis and identified the HIV or
co-infection and advance treatment option.
Market Regional Analysis
North
America dominate the HIV Drugs Market with the highest revenue generating
market with share of more than 43%. The North America dominate this market due
to the rising prevalence of HIV in US, easy availability of medications, new
products launch. Additionally, strong presence of market player, well developed
infra structure, higher number of research favor growth of region.
Europe
having the second-largest market share in Market due to the rising demand for
targeted medication, focus on R&D on HIV Drugs found in Europe. Moreover, government
policies and increasing the elder population in the region significantly
contribute to expand the market.
Asia-Pacific
is estimated the fastest growing CAGR in HIV Drugs Market in forecasted period.
This is due to increasing in healthcare expenditure and the rise in research
and development activities in the pharmaceutical sector.
Competitive Analysis
The
HIV Drugs Market is dominated by a few large companies, such as Boehringer
Ingelheim International GmbH, Cipla Inc., Merck & Co., Inc., AbbVie Inc.,
Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Gilead
Sciences, Inc., Hoffmann-La Roche Ltd, Pfizer Inc., Aurobindo Pharma, Celltrion
Healthcare Co.,Ltd, ViiV Healthcare
There Are Some Of The Recent Developments Of The HIV
Drugs Market:
July
2021 To make darunavir paired with ritonavir (DRV/r) as a second-line
medication for HIV patients living in low and medium-income countries, Unitaid
and Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement
with pharmaceutical company Hetero Labs LTD. The price of the deal is US$ 210
per patient per year.
March
2021 An agreement for collaboration to co-develop and co-commercialize
long-acting HIV medication was made public by Gilead Sciences Inc. and Merck.
To create a two-drug HIV treatment regimen, the firms want to combine
lenacapavir, an experimental capsid inhibitor from Gilead, with islatravir, an
investigational nucleoside reverse transcriptase translocation inhibitor from
Merck.
In
Aug 2018, Merck & Co., Inc. announced that FDA approved its two new
antiretroviral drugs named Delstrigo & Pifetro that helped in treatment of
HIV-1, the most common strain of virus.
By Drug Type
·
Protease Inhibitors
·
Fusion Inhibitors
·
CCR5 Antagonist
·
Nucleosidz
·
Integrase Inhibitors
·
Non-Nucleoside Reverse
Transcriptase Inhibitors
·
By End-User
·
Hospitals & Clinics
·
Specialty Centers
1.
Global
HIV Drugs Market Introduction and Market Overview
1.1. Objectives of the Study
1.2. Global HIV Drugs Market Scope
and Market Estimation
1.2.1. Global HIV Drugs Overall Market
Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2033)
1.2.2. Global HIV Drugs Market Revenue
Share (%) and Growth Rate (Y-o-Y) from 2019 - 2033
1.3. Market Segmentation
1.3.1. Component of Global HIV Drugs
Market
1.3.2. Technology of Global HIV Drugs
Market
1.3.3. End-user of Global HIV Drugs
Market
1.3.4. Region of Global HIV Drugs
Market
2.
Executive Summary
2.1. Global HIV Drugs Market Industry Trends under COVID-19 Outbreak
2.1.1. Global COVID-19 Status Overview
2.1.2. Influence of COVID-19 Outbreak
on Global HIV Drugs Market
Industry Development
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Limitations
2.2.3. Opportunities
2.2.4. Impact Analysis of Drivers and Restraints
2.3. Pricing Trends Analysis &
Average Selling Prices (ASPs)
2.4. Key Mergers & Acquisitions,
Expansions, JVs, Funding / VCs, etc.
2.5. Porter’s Five Forces Analysis
2.5.1. Bargaining Power of Suppliers
2.5.2. Bargaining Power of Buyers
2.5.3. Threat of Substitutes
2.5.4. Threat of New Entrants
2.5.5. Competitive Rivalry
2.6. Value Chain / Ecosystem Analysis
2.7. Russia-Ukraine War Impacts
Analysis
2.8. Economic Downturn Analysis
2.9. Market Investment Opportunity
Analysis (Top Investment Pockets), By Segments & By Region
3.
Global HIV Drugs Market Estimates & Historical Trend Analysis (2019 -
2022)
4.
Global HIV Drugs Market Estimates & Forecast Trend Analysis, Drug
Type
4.1. Global HIV Drugs Market Revenue
(US$ Mn) Estimates and Forecasts, Drug Type, 2019 to 2033
4.1.1. Protease Inhibitors
4.1.2. Fusion Inhibitors
4.1.3. CCR5 Antagonist
4.1.4. Nucleoside
4.1.5. Integrase Inhibitors
4.1.6. Non-Nucleoside Reverse
Transcriptase Inhibitors
5.
Global HIV Drugs Market Estimates & Forecast Trend Analysis, by
End-user
5.1. Global HIV Drugs Market Revenue
(US$ Mn) Estimates and Forecasts, by End-user, 2019 to 2033
5.1.1. Hospitals & Clinics
5.1.2. Specialty Centers
6.
Global HIV Drugs Market Estimates & Forecast Trend Analysis,
by Region
6.1. Global HIV Drugs Market Revenue
(US$ Mn) Estimates and Forecasts, by Region, 2019 to 2033
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7.
North
America HIV Drugs Market: Estimates & Forecast Trend Analysis
7.1.
North
America HIV Drugs Market Assessments & Key Findings
7.1.1. North America HIV Drugs Market
Introduction
7.1.2. North America HIV Drugs Market
Size Estimates and Forecast (US$ Million) (2019 – 2033)
7.1.2.1. Drug Type
7.1.2.2. By End-user
7.1.2.3. By Country
7.1.2.3.1. The U.S.
7.1.2.3.2. Canada
7.1.2.3.3. Mexico
8.
Europe
HIV Drugs Market: Estimates & Forecast Trend Analysis
8.1. Europe HIV Drugs Market
Assessments & Key Findings
8.1.1. Europe HIV Drugs Market
Introduction
8.1.2. Europe HIV Drugs Market Size
Estimates and Forecast (US$ Million) (2019 – 2033)
8.1.2.1. Drug Type
8.1.2.2. By End-user
8.1.2.3.
By
Country
8.1.2.3.1. Germany
8.1.2.3.2. U.K.
8.1.2.3.3. France
8.1.2.3.4. Italy
8.1.2.3.5. Spain
8.1.2.3.6. Russia
8.1.2.3.7. Rest of Europe
9.
Asia
Pacific HIV Drugs Market: Estimates & Forecast Trend Analysis
9.1. Asia Pacific Market Assessments
& Key Findings
9.1.1. Asia Pacific HIV Drugs Market
Introduction
9.1.2. Asia Pacific HIV Drugs Market
Size Estimates and Forecast (US$ Million) (2019 – 2033)
9.1.2.1. Drug Type
9.1.2.2. By End-user
9.1.2.3.
By
Country
9.1.2.3.1. China
9.1.2.3.2. Japan
9.1.2.3.3. India
9.1.2.3.4. Australia
9.1.2.3.5. South Korea
9.1.2.3.6. ASEAN
9.1.2.3.7. Rest of Asia Pacific
10. Middle East & Africa HIV
Drugs Market: Estimates & Forecast
Trend Analysis
10.1. Middle East & Africa Market
Assessments & Key Findings
10.1.1. Middle
East & Africa HIV
Drugs Market Introduction
10.1.2. Middle
East & Africa HIV
Drugs Market Size Estimates and Forecast (US$ Million) (2019 – 2033)
10.1.2.1. Drug Type
10.1.2.2. By End-user
10.1.2.3. By Country
10.1.2.3.1. U.A.E.
10.1.2.3.2. Saudi Arabia
10.1.2.3.3. Egypt
10.1.2.3.4. South Africa
10.1.2.3.5. Rest of Middle East & Africa
11. South America
HIV Drugs Market: Estimates &
Forecast Trend Analysis
11.1. South America Market Assessments
& Key Findings
11.1.1. South America HIV Drugs Market
Introduction
11.1.2. South America HIV Drugs Market
Size Estimates and Forecast (US$ Million) (2019 – 2033)
11.1.2.1. Drug Type
11.1.2.2. By End-user
11.1.2.3. By Country
11.1.2.3.1. Brazil
11.1.2.3.2. Argentina
11.1.2.3.3. Colombia
11.1.2.3.4. Rest of South America
12. Competition Landscape
12.1. Global HIV Drugs Market
Competition Matrix & Benchmarking, by Leading Players / Innovators /
Emerging Players / New Entrants
12.2. Global HIV Drugs Market
Competition White Space Analysis, By End-user
12.3. Global HIV Drugs Market
Competition Heat Map Analysis, By End-user
12.4. Global HIV Drugs Market
Concentration & Company Market Shares (%) Analysis, 2022
13. Company Profiles
13.1. Boehringer Ingelheim International GmbH.
13.1.1. Company Overview & Key Stats
13.1.2. Financial Performance & KPIs
13.1.3. Product Portfolio
13.1.4. Business Strategy & Recent
Developments
* Similar details would be provided
for all the players mentioned below
14.
Cipla Inc.
15.
Merck & Co., Inc.
16.
AbbVie Inc.
17.
Bristol-Myers Squibb Company
18.
Teva Pharmaceutical Industries Ltd
19.
Gilead Sciences, Inc.
20.
Hoffmann-La Roche Ltd
21.
Pfizer Inc.
22.
Aurobindo Pharma
23.
Celltrion Healthcare Co.,Ltd
24. ViiV
Healthcare.
25. Research
Methodology
25.1. External Transportations /
Databases
25.2. Internal Proprietary Database
25.3. Primary Research
25.4. Secondary Research
25.5. Assumptions
25.6. Limitations
25.7. Report FAQs
26. Research Findings & Conclusion
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
HIV Drugs Market was valued at USD 22,500 million in 2022 and is estimated to grow at a CAGR of 3.90%.
Boehringer Ingelheim International GmbH, Cipla Inc., Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Gilead Sciences, Inc., Hoffmann-La Roche Ltd, Pfizer Inc., Aurobindo Pharma, Celltrion Healthcare Co.,Ltd, ViiV Healthcare.
North America dominates the market with an active share of 43%, while North America is estimated to grow at a higher CAGR of 4.1%.
Only Three Thousand Four Hundred Ninety Nine US dollar
Only Four Thousand Four Hundred Ninety Nine US dollar
Only Five Thousand Four Hundred Ninety Nine US dollar